Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies.

Autor: Venceslau-Carvalho AA; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: alexiabiotec@usp.br., Teixeira de Pinho Favaro M; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: favaro.mtp@gmail.com., Ramos Pereira L; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: lennon_rp@hotmail.com., Rodrigues-Jesus MJ; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: modrigues4@gmail.com., Santos Pereira S; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: samuelbiomedicina@usp.br., Andreata-Santos R; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: robert_andreata@hotmail.com., Dos Santos Alves RP; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: rubens.bmc@gmail.com., Castro-Amarante MF; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: mfamarante@gmail.com., Bitencourt Rodrigues K; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: karinebitencourt@usp.br., Ramos da Silva J; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: jamile@usp.br., Rahal Guaragna Machado R; Laboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: rafaelmachado@usp.br., Dos Passos Cunha M; Laboratory of Molecular Evolution and Bioinformatics, Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil. Electronic address: marieltondospassos@gmail.com., Marinho de Andrade Zanotto P; Laboratory of Molecular Evolution and Bioinformatics, Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil. Electronic address: pzanotto@usp.br., Luzetti Fotoran W; Unit for Drug Development and Plasmodium Molecular Biology, Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, Brazil. Electronic address: wesleylfw@hotmail.com., Wunderlich G; Unit for Drug Development and Plasmodium Molecular Biology, Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, Brazil. Electronic address: gwunder@usp.br., Durigon EL; Laboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: eldurigo@usp.br., de Souza Ferreira LC; Vaccine Development Laboratory, Microbiology Department and Parasitology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: lcsf@usp.br.
Jazyk: angličtina
Zdroj: Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2021 Oct; Vol. 37, pp. 102445. Date of Electronic Publication: 2021 Jul 22.
DOI: 10.1016/j.nano.2021.102445
Abstrakt: Chikungunya virus (CHIKV) is responsible for a self-limited illness that can evolve into long-lasting painful joint inflammation. In this study, we report a novel experimental CHIKV vaccine formulation of lipid nanoparticles loaded with a recombinant protein derived from the E2 structural protein. This antigen fragment, designated ∆E2.1, maintained the antigenicity of the native viral protein and was specifically recognized by antibodies induced in CHIKV-infected patients. The antigen has been formulated into nanoparticles consisting of nano-multilamellar vesicles (NMVs) combined with the adjuvant monophosphoryl lipid A (MPLA). The vaccine formulation demonstrated a depot effect, leading to controlled antigen release, and induced strong antibody responses significantly higher than in mice immunized with the purified protein combined with the adjuvant. More relevantly, E2-specific antibodies raised in mice immunized with ∆E2.1-loaded NMV-MPLA neutralized CHIKV under in vitro conditions. Taken together, the results demonstrated that the new nanoparticle-based vaccine formulation represents a promising approach for the development of effective anti-CHIKV vaccines.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: